If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBrown Advisory Regulatory News (BASC)

Share Price Information for Brown Advisory (BASC)

Share Price is delayed by 15 minutes
Get Live Data
1,665.00    57.50 (3.58%)
Bid:
1,595.00
Ask:
1,640.00
Spread: 45.00 (2.821%)
Market Cap: £184.02m
BASC Live PriceLast checked at - London Stock Exchange

Intraday Brown Advisory Share Chart

Strategic Review

Today 07:00

RNS Number : 4018L
Brown Advisory US Smaller Cos. PLC
08 July 2026
 

8 July 2026

For immediate release

 

Brown Advisory US Smaller Companies PLC

 

Legal Entity Identifier (LEI): 549300HKKL9K1NY4TW55

 

Strategic Review

 

The Board announces that it is conducting a Strategic Review of the future of the Company.

 

The Board continues to have confidence in the Portfolio Manager's philosophy and process, and in their ability to deliver positive results over the long term, as demonstrated historically. The Board also remains very positive on the prospects for US smaller companies as an asset class, where valuations are particularly attractive. However, the Board also recognises that more recent performance, despite delivering strong returns in absolute terms over the last year, has lagged the Company's benchmark by a significant margin. 

 

In the past 18 months, the Board has taken a number of actions aimed at enhancing the attractiveness of the Company and delivering value for shareholders. These include the reduction in management fees, effective from 1 January 2025, with fees now based on the lower of market capitalisation and NAV. The Board also remains committed to the use of share buybacks with the aim of reducing discount volatility.

 

The Board is cognisant of the Company's three-yearly continuation vote, to be held at this year's Annual General Meeting, and has been actively engaging with shareholders to understand their views.

 

Feedback from shareholders has been broadly supportive of the Company's investment objective and policy, as well as the processes and resources of the Portfolio Manager. There is also significant support for the Company's existing discount control mechanisms, including the three-yearly continuation vote, the five-year performance-related tender offer scheduled for 2028, and the use of share buybacks. 

 

However, a number of shareholders have indicated a preference for a liquidity opportunity in the shorter term. 

 

Against this backdrop, the Board is considering a range of strategic options, including the provision of a significant cash exit opportunity for shareholders. In evaluating these options, the Board will also have regard to the scale of the Company following any such transaction. 

 

The Strategic Review remains ongoing and there can be no certainty to its outcome. The Board will provide a further update in due course, taking into account the timing of the continuation vote at this year's AGM.

 

As part of the Review, the Board will not actively consider the option of a transaction that would be subject to the Takeover Code, and do not believe such a transaction is a possible outcome of that Review. 

 

Enquiries:

Brown Advisory US Smaller Companies PLC

Via Lansons

Stephen White (Chairman)

 

Singer Capital Markets (Corporate Broker) 020 7496 3000

Mark Bloomfield / James Fischer (Investment Banking)

Alan Geeves / Sam Greatrex / William Gumpel (Sales)

 

Lansons

Ed Hooper 07783 387713

edh@lansons.com 

 

Important Information

This announcement contains information that is inside information for the purposes of the Market Abuse Regulation (EU) No 596/2014 as implemented in the UK. The person responsible for arranging for the release of this announcement on behalf of the Company is Stephen White, Chairman.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDFAWEMSESW
Date   Source Headline
20th Apr 202611:30 amRNSNet Asset Value(s)
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 202610:39 amRNSNet Asset Value(s)
16th Apr 202610:11 amRNSNet Asset Value(s)
16th Apr 20269:00 amRNSPortfolio Update
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 202610:35 amRNSNet Asset Value(s)
14th Apr 202610:05 amRNSNet Asset Value(s)
13th Apr 20269:59 amRNSNet Asset Value(s)
10th Apr 202610:16 amRNSNet Asset Value(s)
9th Apr 202610:48 amRNSNet Asset Value(s)
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 202610:50 amRNSNet Asset Value(s)
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 202612:17 pmRNSNet Asset Value(s)
7th Apr 202610:53 amRNSNet Asset Value(s)
7th Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 20269:57 amRNSNet Asset Value(s)
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 202610:01 amRNSNet Asset Value(s)
30th Mar 202610:48 amRNSNet Asset Value(s)
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 202610:47 amRNSNet Asset Value(s)
25th Mar 20269:56 amRNSNet Asset Value(s)
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 202610:31 amRNSNet Asset Value(s)
23rd Mar 20269:44 amRNSNet Asset Value(s)
20th Mar 202610:13 amRNSNet Asset Value(s)
19th Mar 202610:32 amRNSNet Asset Value(s)
18th Mar 202610:05 amRNSNet Asset Value(s)
17th Mar 20269:56 amRNSNet Asset Value(s)
16th Mar 202610:48 amRNSNet Asset Value(s)
13th Mar 202610:24 amRNSNet Asset Value(s)
13th Mar 20269:00 amRNSPortfolio Update
13th Mar 20269:00 amRNSPortfolio Update
12th Mar 20269:59 amRNSNet Asset Value(s)
12th Mar 20269:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSHolding(s) in Company
11th Mar 202610:41 amRNSNet Asset Value(s)
10th Mar 202610:40 amRNSNet Asset Value(s)
9th Mar 202611:18 amRNSNet Asset Value(s)
6th Mar 202610:21 amRNSNet Asset Value(s)
5th Mar 20269:46 amRNSNet Asset Value(s)
4th Mar 20269:58 amRNSNet Asset Value(s)
3rd Mar 202611:06 amRNSNet Asset Value(s)
2nd Mar 202611:04 amRNSNet Asset Value(s)
27th Feb 20269:48 amRNSNet Asset Value(s)
26th Feb 202610:06 amRNSNet Asset Value(s)
25th Feb 202610:08 amRNSNet Asset Value(s)
24th Feb 20269:57 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.